User login
Key clinical point: A survey-based study shows higher chemotherapy use in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with poor prognostic factors.
Major finding: At least 1 poor prognostic factor was reported in 63% of patients, with varying degrees of overlap between factors. The ability of patients to maintain usual activities was more common in patients without poor prognostic factors. Chemotherapy was prescribed more frequently in patients with poor prognostic factors, whereas endocrine therapy and nonopioid analgesic were more common in patients without poor prognostic factors.
Study details: Real-world data were derived from a large multinational Adelphi Real World Disease Specific Programme survey of 410 oncologists and 2,259 patients with HR-positive, HER-negative advanced breast cancer.
Disclosures: This study was supported by Eli Lilly and Company Ltd, Windlesham, UK. The authors were employees of or received consulting/advisory fees and/or honoraria from Eli Lilly and Company.
Source: Davie A et al. ESMO Open. 2021;6(4):10226 doi: 10.1016/j.esmoop.2021.100226.
Key clinical point: A survey-based study shows higher chemotherapy use in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with poor prognostic factors.
Major finding: At least 1 poor prognostic factor was reported in 63% of patients, with varying degrees of overlap between factors. The ability of patients to maintain usual activities was more common in patients without poor prognostic factors. Chemotherapy was prescribed more frequently in patients with poor prognostic factors, whereas endocrine therapy and nonopioid analgesic were more common in patients without poor prognostic factors.
Study details: Real-world data were derived from a large multinational Adelphi Real World Disease Specific Programme survey of 410 oncologists and 2,259 patients with HR-positive, HER-negative advanced breast cancer.
Disclosures: This study was supported by Eli Lilly and Company Ltd, Windlesham, UK. The authors were employees of or received consulting/advisory fees and/or honoraria from Eli Lilly and Company.
Source: Davie A et al. ESMO Open. 2021;6(4):10226 doi: 10.1016/j.esmoop.2021.100226.
Key clinical point: A survey-based study shows higher chemotherapy use in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with poor prognostic factors.
Major finding: At least 1 poor prognostic factor was reported in 63% of patients, with varying degrees of overlap between factors. The ability of patients to maintain usual activities was more common in patients without poor prognostic factors. Chemotherapy was prescribed more frequently in patients with poor prognostic factors, whereas endocrine therapy and nonopioid analgesic were more common in patients without poor prognostic factors.
Study details: Real-world data were derived from a large multinational Adelphi Real World Disease Specific Programme survey of 410 oncologists and 2,259 patients with HR-positive, HER-negative advanced breast cancer.
Disclosures: This study was supported by Eli Lilly and Company Ltd, Windlesham, UK. The authors were employees of or received consulting/advisory fees and/or honoraria from Eli Lilly and Company.
Source: Davie A et al. ESMO Open. 2021;6(4):10226 doi: 10.1016/j.esmoop.2021.100226.